Interferon Beta-1B

Products

Interferon beta-1b is commercially available as a powder and solvent for the preparation of a solution for injection (Betaferon). It has been approved in many countries since 1995.

Structure and properties

Interferon beta-1b is a recombinant protein of 165 amino acids with a molecular mass of approximately 18,500 Da. It is derived from an E. coli strain and, unlike interferonum beta-1a, is not glycosylated. It is therefore somewhat less similar to the natural protein than interferon beta-1a.

Effects

Interferon beta-1b (ATC L03AB08) has antiviral, antiproliferative, antitumor, and immunomodulatory properties. It slows disease progression, decreases the frequency of relapses, and reduces their severity.

Indications

For the treatment of multiple sclerosis.

Dosage

According to the SmPC. The injection solution is usually injected subcutaneously every other day. The injection site should be changed regularly.

Contraindications

  • Hypersensitivity
  • History of major depressive disorder and/or suicidal tendencies in patients
  • Hepatic insufficiency
  • Inadequately controlled epilepsy

Full precautions can be found in the drug label.

Interactions

Interferons are known to be CYP inhibitors. Corresponding drug-drug interactions are possible.

Adverse effects

The most common possible adverse effects include flu-like symptoms, headache, muscle pain, abdominal pain, elevated liver enzyme levels, blood count abnormalities, skin rash, urinary urgency, sleep disturbances, incoordination, and application site reactions. Interferons may rarely cause liver damage.